COMMUNIQUÉS West-GlobeNewswire

IBA and Framatome join forces to industrialize Astatine-211 production for cancer therapies
16/10/2026
Louvain-la-Neuve, Belgium, and Paris, France, 16 October 2026, 8:00 a.m. – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and radiopharmaceutical production solutions, [...]
IBA et Framatome s’associent pour industrialiser la production d’Astate-211 au service des thérapies contre le cancer
16/10/2026
Louvain-la-Neuve, Belgique, et Paris, France, le 16 octobre 2026, 8h00 – IBA (Ion Beam Applications, EURONEXT), leader mondial des technologies d'accélérateurs de particules et des solutions de production en médecine [...]
FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)
16/10/2026
FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (double vision), with a favourable safety profile, [...]
Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Enrolls First Patient in Phase Ib/II Combination Trial in Metastatic Colorectal Cancer
16/10/2026
Extending the Company's Immunologically Cold Tumor Strategy into Colorectal Cancer NANJING, China , Oct. 16, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887. [...]
City Therapeutics Announces Pricing of Upsized Initial Public Offering
16/10/2026
CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY) (“City” or “City Therapeutics”), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi [...]
Paretofit Announces Founder Tobias Burkhardt's Feature in Prime Today on Sustainable Performance for Entrepreneurs
15/10/2026
The cover story explores how the German health sociologist applies evidence-based 80/20 principles to help self-employed professionals and entrepreneurs build sustainable personal health systems. Cologne, Germany, Oct. [...]
Conexeu Sciences Announces $5 Million Private Placement Led by Existing Shareholders, Management and Directors
15/10/2026
Financing involving participation from the CEO and Chief Commercial Officer, supports manufacturing scale-up, regulatory testing and preclinical work toward the Company’s planned FDA 510(k) submission in the first [...]
Freenome to Report Third Quarter 2026 Financial Results on November 10, 2026
15/10/2026
BRISBANE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, today announced that the Company plans to release its [...]
LifeStance to Host Third Quarter 2026 Earnings Conference Call on November 5, 2026
15/10/2026
SCOTTSDALE, Ariz., Oct. 15, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental healthcare, will issue its third quarter 2026 earnings [...]
Mobia Medical to Report Third Quarter 2026 Financial Results on November 5, 2026
15/10/2026
AUSTIN, Texas, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced that [...]
Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
15/10/2026
CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, [...]
Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026
15/10/2026
SALT LAKE CITY, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2026 earnings conference call at 4: [...]
LB Pharmaceuticals to Participate in Upcoming Investor Events
15/10/2026
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
15/10/2026
CONSHOHOCKEN, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors
15/10/2026
ROCKVILLE, MD, Oct. 15, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, [...]
Full 12-Month Data from the ACCCESS U.S. Pivotal Study in Complete Concentric Collapse Patients Presented at ISSS 2026
15/10/2026
Full 12-Month Data from the ACCCESS U.S. Pivotal Study in Complete Concentric Collapse Patients Presented at ISSS 2026 Genio® bilateral stimulation delivered a 74.3% median reduction in AHI at 12 months, with no device [...]
Données Complètes à 12 Mois de l’Étude Pivot Américaine ACCCESS chez les Patients Atteints de Collapsus Concentrique Complet Présentées à l’ISSS 2026
15/10/2026
Données Complètes à 12 Mois de l’Étude Pivot Américaine ACCCESS chez les Patients Atteints de Collapsus Concentrique Complet Présentées à l’ISSS 2026 La stimulation bilatérale Genio® a permis une réduction médiane de 74 [...]
Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List
15/10/2026
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj ® (revumenib), the [...]
Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
15/10/2026
OPGx-BEST1 showed improved retinal sensitivity in 75% of evaluable participants in the initial low-dose Cohort 1 of the Company’s Phase 1/2 clinical trial, supporting further clinical development New BEST1 data analyses [...]

Pages